Table 3.
Linear regression models to evaluate the association of PCSK9 levels with severity of depression (BDI-II score)
| β | SE | P-value | |
|---|---|---|---|
| Univariate model | |||
| Intercept | 249.98 | 9.85 | <.0001 |
| BDI-II Score (for unit increase) | 2.75 | 0.68 | <.0001 |
| Adjusted model | |||
| Intercept | 188.43 | 53.14 | 0.0004 |
| BDI-II Score (for unit increase) | 1.85 | 0.69 | 0.0074 |
| Age, years | − 0.07 | 0.48 | 0.8824 |
| Gender | 0.0004 | ||
| Male | − 46.10 | 12.86 | |
| Female | Ref | ||
| BMI | −0.29 | 1.00 | 0.7673 |
| Smoking status | 0.0157 | ||
| Current smoker | 21.29 | 15.67 | 0.1752 |
| Former smoker | 34.13 | 11.88 | 0.0043 |
| Never smoker | Ref | ||
| Non-HDL, mg/dl | 0.49 | 0.15 | 0.0015 |
| Statin medications | |||
| Yes | 63.35 | 21.22 | 0.0022 |
| No | Ref | ||
| Triglyceride, mg/dl | 0.07 | 0.08 | 0.3730 |
| Antihypertensive medications | |||
| Yes | 13.07 | 13.9 | 0.3479 |
| No | Ref | ||
| Antidepressive medications | |||
| Yes | 0.34 | 18.02 | 0.9848 |
| No | Ref | ||
BDI Beck Depression Inventory, BMI body mass index, HDL high-density lipoprotein, PCSK9 pro-protein convertase subtilisin/kexin type 9, Ref stands for reference value